Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56.3M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
11.8M
-
Shares change
-
+4.21M
-
Total reported value, excl. options
-
$19.2M
-
Value change
-
+$6.86M
-
Number of buys
-
22
-
Number of sells
-
-12
-
Price
-
$1.63
Significant Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q3 2025
51 filings reported holding QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2025.
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.8M shares
of 56.3M outstanding shares and own 20.96% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (3.07M shares), VANGUARD GROUP INC (1.76M shares), MILLENNIUM MANAGEMENT LLC (1.39M shares), IEQ CAPITAL, LLC (981K shares), ADAR1 Capital Management, LLC (775K shares), Almitas Capital LLC (495K shares), RENAISSANCE TECHNOLOGIES LLC (469K shares), GEODE CAPITAL MANAGEMENT, LLC (437K shares), BlackRock, Inc. (345K shares), and HighTower Advisors, LLC (309K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.